Document is current
Any future updates will be listed below
-
Authors
Lofiego, Maria Fortunata
Tufano, Rossella
Bello, Emma
Solmonese, Laura
Marzani, Francesco
Piazzini, Francesca
Celesti, Fabrizio
Caruso, Francesca Pia
Noviello, Teresa Maria Rosaria
Mortarini, Roberta
Anichini, Andrea
Ceccarelli, Michele
Calabrò, Luana
Maio, Michele
Coral, Sandra
Di Giacomo, Anna Maria
Covre, Alessia
,
-
Funding
Funding for this research was provided by:
Ministero della Salute (NET-2016-02361632, NET-2016-02361632)
Fondazione AIRC (ID.21073, ID.21073, ID.21073, ID.21073)
- License Information
-
More Information
Article History
Received: 24 December 2024
Accepted: 31 January 2025
First Online: 18 February 2025
Declarations
:
: Not applicable.
: Not applicable.
: AMDG has served as consultant and/or advisor to Incyte, Pierre Fabre, Glaxo Smith Kline, Bristol-Myers Squibb, Merck Sharp Dohme, and Sanofi and has received compensated educational activities from Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre and Sanofi. MM has served as consultant and/or advisor to Roche, Bristol-Myers Squibb, Merck Sharp Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, Glaxo Smith Kline, Sciclone, Sanofi, Alfasigma, and Merck Serono; and owns shares in Theravance and Epigen Therapeutics Srl. MC serves as consultant and/or advisor to Moderna Therapeutics and is founder and owns shares of Immunomica srl. AC and SC own shares in Epigen Therapeutics Srl. Other authors have nothing to declare.
